Biotech Companies WuXi AppTec and WuXi Biologics Surge Following Potential Divestment Amid U.S. Legislation

Friday, 4 October 2024, 10:00

Biotech companies WuXi AppTec and WuXi Biologics surged as news of potential divestments emerged in light of U.S. legislation targeting Chinese firms. The rise followed reports that both companies are considering selling operations to mitigate the impact of the Biosecure Act. Their recent market performance underscores the growing tensions between the U.S. and China regarding support for biotech companies.
Scmp
Biotech Companies WuXi AppTec and WuXi Biologics Surge Following Potential Divestment Amid U.S. Legislation

Market Surge of Biotech Companies

Shares of WuXi AppTec and WuXi Biologics experienced substantial gains, attributed to their plans to divest some operations amidst heightened legislative scrutiny. WuXi AppTec's shares surged nearly 12% reaching HK$67.10, while WuXi Biologics saw a nearly 15% increase to HK$21.45.

Session Highlights

  • WuXi Advanced Therapies, a division of WuXi AppTec, is on the market.
  • WuXi Biologics is exploring interest in its European production sites.
  • Both companies aim to mitigate risks from the Biosecure Act, pending Senate approval.

Legislative Background

The U.S. House of Representatives passed a bill that targets several Chinese biotech companies, including WuXi and BGI Group. This legislation could hinder operations of these firms if enacted.

Tension in the Biotechnology Sector

The Biden administration has stressed the need to cut ties with foreign entities that pose potential risks to national security. Chinese biotech firms have found themselves in a challenging geopolitical landscape, as export restrictions increase.

Financial Performance Report

Despite recent gains, WuXi companies have faced declining revenue reflecting broader industry challenges. In the first half of the year, WuXi AppTec reported a revenue drop of 8.6%, highlighting the impact of ongoing legislative changes.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe